翻訳と辞書 |
Vorsetuzumab mafodotin : ウィキペディア英語版 | Vorsetuzumab mafodotin
Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) directed to the protein CD70 designed for the treatment of cancer.〔(Statement On A Nonproprietary Name Adopted By The USAN Council: Vorsetuzumab Mafodotin ), ''American Medical Association.〕 It is a humanized monoclonal antibody, vorsetuzumab, conjugated with noncleavable monomethyl auristatin F (MMAF), a cytotoxic agent. This drug was developed by Seattle Genetics, Inc. The drug completed phase I clinical trials for renal cell carcinoma,〔Clinical trials for SGN-75 ("Clinicaltrials.gov" )〕 but development was discontinued in 2013.〔(Seattle Genetics Third Quarter 2013 Financial Report )〕 No reason was given but SG plan to start clinical trials of SGN-CD70A in 2014.〔 == References == 〔
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Vorsetuzumab mafodotin」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|